A trial looking at pembrolizumab for people with non small cell lung cancer (PePS2)

Overview

Cancer types:

Lung cancer, Non small cell lung cancer (NSCLC)

Status:

Results

Phase:

Phase 2

Details

This trial was for people whose general health and activity wasn’t very good because of their cancer.

Doctors measure your general health and activity using an internationally recognised scale called performance status. This trial is for people with a performance status of 2.

This trial was open for people to join between November 2016 and December 2017 and allowed 2 years for treatment and patient follow up. The team published the results in March 2020.

Recruitment start: 7 November 2016

Recruitment end: 31 December 2017